Abstract
Genetic variation in the ADRB2 gene has been hypothesized to have a role in differential response to beta-agonist (BA) therapy in asthma. However, study results have been inconsistent and the issue remains controversial. Furthermore, the impact of ADRB2 genetic variation on BA response in chronic obstructive pulmonary disease (COPD) patients has not been thoroughly studied. We carried out a large pharmacogenetic analysis testing for an association between common ADRB2 polymorphisms and indacaterol response in COPD patients. A total of 648 indacaterol-treated patients enrolled in two large randomized phase III studies were genotyped for the most commonly studied polymorphisms in the ADRB2 gene: Gly16Arg, Gln27Glu, Thr164Ile, and a variant in the 5′ untranslated region (rs1042711). Our analysis showed little evidence for the association between these ADRB2 variants and indacaterol response, suggesting that ADRB2 genetic variation is unlikely to have a major role in differential response to indacaterol treatment in COPD patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Contopoulos-Ioannidis DG, Kouri I, Ioannidis JP . Pharmacogenetics of the response to beta 2 agonist drugs: a systematic overview of the field. Pharmacogenomics 2007; 8: 933–958.
Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162: 75–80.
Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI . Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55: 762–767.
Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505–1512.
Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R . Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184–3188.
Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005; 171: 563–570.
Hawkins GA, Weiss ST, Bleecker ER . Clinical consequences of ADRbeta2 polymorphisms. Pharmacogenomics 2008; 9: 349–358.
Wechsler ME, Lehman E, Lazarus SC, Lemanske Jr RF, Boushey HA, Deykin A et al. Beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173: 519–526.
Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118: 809–816.
Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M . Effect of ADRB2 polymorphisms on response to long acting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370: 2118–2125.
Kim WJ, Hersh CP, DeMeo DL, Reilly JJ, Silverman EK . Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. Respir Med 2009; 103: 552–557.
Mokry M, Joppa P, Slaba E, Zidzik J, Habalova V, Kluchova Z et al. Beta2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD. Med Sci Monit 2008; 14: CR392–CR398.
Hizawa N, Makita H, Nasuhara Y, Betsuyaku T, Itoh Y, Nagai K et al. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 2007; 132: 1485–1492.
Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H et al. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008; 186: 381–386.
Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155–162.
Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37: 273–279.
Acknowledgements
We thank all the investigators and patients who participated in the clinical trials QAB149B2335S (clinicaltrials.gov: NCT00463567) and QAB149B2336 (clinicaltrials.gov: NCT00567996). We also thank M Healey for her assistance with data management. This study was funded by Novartis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
All authors are current or past employees of Novartis.
Additional information
Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Yelensky, R., Li, Y., Lewitzky, S. et al. A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients. Pharmacogenomics J 12, 484–488 (2012). https://doi.org/10.1038/tpj.2011.54
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2011.54
